2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Consolidated Water reported third-quarter 2026 revenue of $30.9 million, down 11.9% from $35.1 million, with lower services and manufacturing revenue partly offset by higher retail and bulk revenue. Net income attributable to company stockholders fell to $2.3 million, or $0.14 per diluted share, from $5.5 million, or $0.34 per diluted share, a year earlier, so shareholders saw both lower sales and lower per-share profit.
Q3 2026 revenue $30.9 million, down 11.9% from $35.1 million; services revenue fell 31.7% to $9.8 million and manufacturing revenue fell 39.7% to $2.8 million
Q3 net income attributable to stockholders $2.3 million ($0.14 diluted EPS) vs $5.5 million ($0.34) in Q3 2025
Nine-month revenue $93.8 million, down 8.5%; cash and cash equivalents $129.2 million as of September 30, 2026
Microvast reported third-quarter 2026 revenue of $45.8 million, down 62.8% from $123.3 million a year earlier, and a net loss of $76.8 million, including $35.7 million of non-cash impairment charges. The company said its available cash is expected to be insufficient to meet obligations over the next twelve months, and its going concern doubt has not been alleviated, so shareholders face significant uncertainty about refinancing its debt.
Q3 2026 revenue was $45.8 million versus $123.3 million in Q3 2025; gross margin fell to 5.2% from 37.6%.
Q3 2026 net loss was $76.8 million, compared with a net loss of $1.5 million in Q3 2025.
Cash, cash equivalents and restricted cash were $124.4 million at September 30, 2026; $41.7 million of convertible bonds are due on or before January 31, 2027.
Net cash used in operating activities was $65.4 million for the nine months ended September 30, 2026.
Trevi Therapeutics reported a third-quarter 2026 net loss of $21.5 million, or $0.13 per share, up from $11.8 million, or $0.08 per share, a year earlier, as research and development expenses rose to $19.1 million from $10.1 million. The company ended the quarter with $299.4 million in cash, cash equivalents and marketable securities and said this funds cash runway into 2030, which matters to shareholders because spending is rising and the filing shows no revenue line.
Net loss of $21.5 million for the quarter ended September 30, 2026, versus $11.8 million in the same period of 2025
Research and development expenses of $19.1 million, up from $10.1 million, driven by Phase 3 OCEAN-1 and OCEAN-2 and Phase 2b LAKE trials
Cash, cash equivalents and marketable securities of $299.4 million at September 30, 2026; the company expects cash runway into 2030
Positive FDA meeting in October 2026 on the non-IPF ILD program; Phase 2 dose-ranging trial expected to start in the first quarter of 2027
Surrozen reported a third-quarter 2026 net loss of $129.7 million, up from $71.6 million a year earlier, with no related-party research revenue after the TCGFB collaboration ended. Most of the loss came from non-cash fair value changes in tranche and warrant liabilities, and the company said October financings lifted pro forma cash to about $220.3 million, with runway into 2029.
Net loss was $129.7 million for the quarter ended September 30, 2026, including a $73.9 million non-cash loss on the tranche liability.
Research service revenue from a related party was zero, compared with $1.0 million a year earlier, after the TCGFB collaboration terminated effective November 2025.
Cash and cash equivalents were $100.4 million at September 30, 2026; pro forma cash was about $220.3 million after October financings.
The company plans to expand DUET Phase 2a enrollment from about 60 to 150 patients, with Phase 1b topline data expected in the second half of 2027.
Lineage reported third-quarter 2026 results with total revenue down 1.2% to $1.36 billion, a GAAP net loss of $173 million ($0.68 per diluted share, versus a $0.44 loss a year earlier), and adjusted EBITDA down 7.0% to $317 million. CEO Greg Lehmkuhl said higher oil prices, constrained trucking capacity and tariff uncertainty created headwinds later in the quarter, and the company adjusted its full-year guidance to reflect pressures it expects to continue into the fourth quarter.
Q3 2026 AFFO fell 14.9% to $188 million, and AFFO per share fell 14.1% to $0.73.
Full-year 2026 guidance: adjusted EBITDA of $1.25 billion to $1.27 billion and AFFO per share of $2.86 to $2.98; the filing does not show prior guidance figures.
Quarterly dividend declared at $0.5325 per share, an annualized rate of $2.13 per share.
Same-store occupancy grew year over year for the second consecutive quarter; the conference call is on November 10, 2026, at 8:00 a.m. Eastern Time.
FreightCar America reported third quarter 2026 revenue of $76.5 million, down from $160.5 million a year earlier, and delivered 662 railcars versus 1,304. It posted adjusted EBITDA of $0.1 million and an adjusted net loss of $9.5 million, or $(0.28) per diluted share, compared with adjusted net income of $7.8 million a year earlier. The company reaffirmed its fiscal 2026 outlook, which matters to shareholders because it signals that management still expects the full-year targets it set on October 19.
Q3 2026 revenue was $76.5 million versus $160.5 million in Q3 2025; railcar deliveries were 662 units versus 1,304.
Adjusted EBITDA was $0.1 million (0.2% margin) versus $15.9 million (9.9% margin) a year earlier.
Backlog reached 2,660 units valued at $284.5 million at September 30, 2026, up 28% from $222.0 million.
Fiscal 2026 outlook reaffirmed: 3,100 to 3,300 railcars, revenue of $370 to $410 million, and adjusted EBITDA of $15 to $19 million.
Structure Therapeutics reported a third-quarter 2026 net loss of $144.8 million, up from $65.7 million a year earlier, as research and development expenses rose to $134.6 million from $59.0 million. The company had $1.2 billion in cash, cash equivalents and short-term investments at September 30, 2026, which it says will fund projected operations and key clinical milestones through 2028.
Q3 2026 net loss was $144.8 million, compared with $65.7 million in Q3 2025.
R&D expenses were $134.6 million, up from $59.0 million, mainly due to clinical trial costs.
Cash, cash equivalents and short-term investments were $1.2 billion at September 30, 2026, down from $1.3 billion at June 30, 2026.
Topline data from the Phase 3 ACCOMPLISH program for aleniglipron are expected in the second half of 2028.
Network-1 reported no revenue for the quarter ended September 30, 2026, and a net loss of $2,333,000, or $0.10 per share, compared with a net loss of $560,000, or $0.02 per share, a year earlier. Operating expenses rose to $1,608,000 from $800,000, mainly due to higher litigation-related professional fees, and the company also recorded a $1,060,000 loss on marketable securities in the quarter. For shareholders, the loss grew while revenue stayed at zero, and cash, cash equivalents and marketable securities totaled $31,102,000 as of September 30, 2026.
Q3 2026 revenue was zero, the same as Q3 2025; nine-month revenue fell to zero from $150,000 a year earlier.
Q3 2026 net loss was $2,333,000 ($0.10 per share) versus $560,000 ($0.02 per share) in Q3 2025.
Q3 2026 operating expenses were $1,608,000 versus $800,000, driven by litigation-related professional fees.
Cash, cash equivalents and marketable securities were $31,102,000 as of September 30, 2026; the company declared a $0.05 per share dividend in the quarter.
Attovia Therapeutics reported third quarter 2026 results on November 9, 2026, with a net loss of $22.3 million, up from $13.8 million a year earlier, and no collaboration revenue compared with $0.4 million in the prior-year quarter. The company also disclosed 12-week Phase 1b data for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis, and said it expects two Phase 2 trials to start in the first half of 2027. Cash, cash equivalents, and marketable securities of $395.9 million are expected to fund operations into 2030.
Net loss was $22.3 million for Q3 2026, compared with $13.8 million for Q3 2025.
Collaboration revenue was zero in Q3 2026, compared with $0.4 million in Q3 2025.
Research and development expenses rose to $20.3 million from $12.3 million, driven by ATTO-1310 and preclinical programs.
At Week 12 in chronic pruritus patients, 82% of ATTO-1310-treated patients achieved PP-NRS4 vs. 22% with placebo; Phase 2 ATTUNE trials are on track to start in the first half of 2027.
Ethan Allen reported fiscal 2027 first-quarter results for the period ended September 30, 2026, with consolidated net sales down 11.8% year over year and GAAP diluted EPS falling to $0.07 from $0.41. Adjusted diluted EPS was $0.10 versus $0.43 a year earlier, and the company cited lower sales and tariffs for the margin pressure. The filing contains no updated financial guidance.
Consolidated net sales were $129.6 million, compared with $147.0 million in the prior year period.
GAAP net income was $1.7 million, compared with $10.5 million; GAAP operating margin was 1.3%, compared with 6.8%.
Cash and cash equivalents were $92.2 million at September 30, 2026, after $92.2 million in dividends paid during the quarter, with no outstanding debt.
Maze Therapeutics reported third quarter 2026 results with a net loss of $48.0 million, or $0.79 per share, up from $30.1 million, or $0.66 per share, a year earlier. The increase reflects higher research and development and general and administrative spending, and the company recognized no license revenue in the quarter, so shareholders face a larger loss with no revenue offset in the period.
Q3 2026 net loss was $48.0 million, or $0.79 per share, versus $30.1 million, or $0.66 per share, in Q3 2025.
R&D expenses rose to $40.2 million from $25.2 million, and G&A expenses rose to $11.3 million from $7.8 million.
Cash, cash equivalents and marketable securities were $477.0 million at September 30, 2026, up from $360.0 million at December 31, 2025, and are expected to fund operations into 2029.
Nine-month license revenue of $20.0 million reflects a first-quarter 2026 milestone under the Shionogi license for MZE001.
The Trade Desk reported third-quarter 2026 revenue of $736 million, down 0.5% from a year earlier, and GAAP net income of $38 million, down from $116 million. The board also approved an additional $731 million for share repurchases, bringing total available authorization to $1 billion.
Q3 2026 revenue was $736 million versus $739 million in Q3 2025; GAAP diluted EPS was $0.08 versus $0.23.
Adjusted EBITDA was $266 million versus $317 million a year earlier; the filing cites $44 million in restructuring charges under its 2026 Restructuring Plan.
Fourth-quarter 2026 outlook calls for revenue of at least $755 million and Adjusted EBITDA of at least $280 million.
The board authorized an additional $731 million under the share repurchase program, bringing the total available to $1 billion.
Paradium.AI reported third-quarter 2026 revenue of $20.5 million, down 31.2% from $29.8 million a year earlier, and a net loss of $3.8 million versus net income of $6.9 million in Q3 2025. The company attributed the decline mainly to lower referral traffic, including from Google Discover, which reduced advertising revenue and compressed gross margin to 31.7% from 50.0%.
Revenue was $20.5 million in Q3 2026 versus $29.8 million in Q3 2025, a decline of 31.2%.
Net loss was $3.8 million, or $0.08 per diluted share, compared with net income of $6.9 million in Q3 2025.
Results include a $1.3 million reversal of an employee retention tax credit that was disallowed; the company plans to appeal.
Cash balance was $10.1 million at September 30, 2026.
LifeVantage reported fiscal first-quarter results for the three months ended September 30, 2026, with revenue down 22.0% from a year earlier and a net loss of $0.02 per diluted share, compared with net income of $0.17 per share. The decline was driven mainly by lower active accounts and lower sales of the MindBody GLP-1 System, and the company recorded a $1.0 million inventory obsolescence allowance for that product, which pressured margins.
Revenue was $37.1 million, down 22.0% from $47.6 million a year earlier.
Net loss was $0.2 million, or $0.02 per diluted share, versus net income of $2.2 million, or $0.17 per share, in the prior year period.
Adjusted EPS was $0.05, compared with $0.18 a year earlier; adjusted EBITDA was $1.9 million versus $3.9 million.
Cash and cash equivalents were $13.7 million at September 30, 2026, with no debt outstanding; no shares were repurchased, leaving $58.5 million under the $60 million program.
ArriVent reported third-quarter 2026 results with a net loss of $40.3 million, up from $35.0 million a year earlier, as research and development and general and administrative expenses rose. The company also said its Phase 3 FURVENT trial of firmonertinib did not meet its primary endpoint of progression-free survival, and that Stuart Lutzker, its President of Research and Development and a director, will retire effective December 1, 2026. For shareholders, the trial miss is the central development, with the wider loss and leadership change adding to the negative picture.
FURVENT missed its primary endpoint of progression-free survival by blinded independent central review; median PFS was 11.0 months at 240 mg versus 9.5 months with chemotherapy (HR 0.75; p=0.0654).
Q3 2026 net loss was $40.3 million versus $35.0 million in Q3 2025; collaboration revenue was $5.0 million versus none a year earlier.
Net loss per share was $0.81 versus $0.83 a year earlier; cash and investments were $393.2 million at September 30, 2026, expected to fund operations to mid-2028.
Dr. Stuart Lutzker retires effective December 1, 2026, with a one-time payment of $428,438.21 under a planned retirement agreement; Chief Medical Officer Priti Patel, M.D., will lead R&D from that date.
Immunome reported a third-quarter 2026 net loss of $85.8 million, or $0.76 per share, up from $57.5 million, or $0.65 per share, a year earlier, with no collaboration revenue in either period. Higher research and development and general and administrative spending drove the wider loss, and the company said its $461.6 million in cash and marketable securities should fund operations into 2028.
Net loss was $85.8 million for the quarter ended September 30, 2026, versus $57.5 million a year earlier; loss per share was $0.76 versus $0.65.
Research and development expenses rose to $69.5 million from $49.2 million; general and administrative expenses rose to $20.9 million from $10.9 million.
Cash, cash equivalents and marketable securities totaled $461.6 million as of September 30, 2026, which the company expects to fund operations into 2028.
The FDA set a PDUFA target action date of April 28, 2027 for varegacestat, and updated IM-1021 Phase 1 data are expected at ASH on December 14, 2026.
MBX Biosciences reported a third-quarter 2026 net loss of $62.4 million, up from $21.6 million a year earlier, as research and development and general and administrative expenses both rose sharply. The company said cash, cash equivalents and marketable securities were $481.6 million at September 30, 2026, which it expects to fund operations into 2029, and the filing notes that $20.8 million of the G&A increase was stock-based compensation tied to modified awards for its former chief executive officer.
Net loss was $62.4 million, or $1.29 per share, for the quarter ended September 30, 2026, versus $21.6 million, or $0.63 per share, a year earlier.
R&D expenses rose to $32.0 million from $19.3 million, driven in part by start-up costs for the canvuparatide Phase 3 trial, which started in the third quarter.
G&A expenses rose to $34.3 million from $4.7 million, including $20.8 million of stock-based compensation tied to modified awards for the former CEO.
Cash, cash equivalents and marketable securities were $481.6 million, including $97.6 million net proceeds from at-the-market stock sales.
James River Group Holdings reported a third-quarter 2026 net loss available to common shareholders of $189.4 million, or $4.08 per diluted share, after a non-cash goodwill impairment of $181.8 million. Adjusted net operating loss was $4.4 million, compared with adjusted income of $17.4 million a year earlier, as $19.2 million of adverse reserve development in its Excess and Surplus Lines segment weighed on results. The company said the impairment does not affect its adjusted results, statutory capital or debt covenant compliance, and declared a $0.01 per share cash dividend.
Net loss available to common shareholders was $189.4 million, or $4.08 per diluted share, versus a $948,000 loss ($0.02 per share) in the third quarter of 2025.
Non-cash goodwill impairment of $181.8 million; the goodwill dates to a 2007 acquisition of the company by an investor group.
Adjusted net operating loss of $4.4 million ($0.10 per diluted share) versus adjusted income of $17.4 million ($0.32) a year earlier.
Gross written premium fell 22% to $186.1 million; $0.01 per share dividend payable December 31, 2026 to holders of record December 15, 2026.
Septerna reported third quarter 2026 results, with revenue of $18.9 million, down from $21.5 million a year earlier, and a net loss of $26.6 million, compared with net income of $8.2 million in the same quarter of 2025. The prior-year quarter included a $12.5 million gain on sale of a non-financial asset, and research and development expenses rose to $36.6 million from $24.3 million, so shareholders face a larger loss on lower revenue.
Revenue was $18.9 million for the quarter ended September 30, 2026, versus $21.5 million a year earlier.
Net loss was $26.6 million, or $0.57 per share, versus net income of $8.2 million, or $0.18 per share, a year earlier.
R&D expenses rose to $36.6 million from $24.3 million, and G&A expenses rose to $9.6 million from $7.1 million.
Cash, cash equivalents and marketable securities totaled $565.2 million at September 30, 2026, which the company expects to fund operations at least into mid-2029.
Neurogene Inc. reported third quarter 2026 results, with a net loss of $29.0 million for the three months ended September 30, 2026, up from $21.0 million a year earlier. Higher R&D and G&A spending, driven largely by NGN-401 development and stock-based compensation, drove the increase, and the company said its cash position is expected to fund operations into the first quarter of 2029.
Net loss was $29.0 million for Q3 2026, compared with $21.0 million for Q3 2025.
R&D expenses rose to $23.5 million from $17.2 million, mainly for NGN-401 clinical trial and manufacturing activities.
G&A expenses rose to $8.9 million from $6.6 million, mainly from higher non-cash stock-based compensation.
Cash, cash equivalents and short-term investments were $359.7 million as of September 30, 2026, expected to fund operations into the first quarter of 2029.
Spruce Biosciences reported a third-quarter 2026 net loss of $24.0 million, or $(8.51) per share, up from $8.2 million, or $(14.58) per share, a year earlier. The company also separated its CRHX-101 program into a new subsidiary, Adrenyx Biosciences, and plans to distribute Adrenyx shares to Spruce stockholders, a step its board has not yet approved.
Q3 2026 net loss was $24.0 million, or $(8.51) per share, versus $8.2 million, or $(14.58) per share, in Q3 2025; R&D expenses were $18.1 million.
Cash and cash equivalents were $87.7 million at September 30, 2026, up from $48.9 million at December 31, 2025, which the company says will fund operations and debt obligations into the second half of 2027.
The Distribution of Adrenyx stock is expected in the first half of 2027, but Spruce's board has not yet approved it or set a record date.
Under an amended Avenue loan agreement dated November 6, 2026, up to $15.0 million of Tranche 2 may be drawn between January 1, 2027 and March 31, 2027.
Whitehawk Therapeutics reported a third-quarter 2026 net loss of $21.2 million, up from $17.7 million a year earlier, as research and development expenses rose to $18.1 million from $14.3 million. The company reported no revenue in the quarter and said its cash, cash equivalents and short-term investments of $169.7 million should fund operations into the second half of 2028.
Q3 2026 net loss was $21.2 million, compared with $17.7 million in Q3 2025.
Research and development expenses were $18.1 million, compared with $14.3 million a year earlier.
Cash, cash equivalents and short-term investments were $169.7 million as of September 30, 2026, versus $145.7 million at December 31, 2025.
The Phase 1 trial of HWK-206 began in the U.S., and the FDA granted it Fast Track designation; initial Phase 1 data from HWK-007 and HWK-016 are expected in the first half of 2027.
Compass Therapeutics reported a third-quarter 2026 net loss of $27.2 million, or $0.15 per share, up from $14.3 million, or $0.08 per share, a year earlier. Higher research and development and general and administrative spending drove the increase, and cash and marketable securities fell to $163 million, which the company says will fund operations into 2028.
Q3 2026 net loss was $27.2 million ($0.15 per share) versus $14.3 million ($0.08 per share) in Q3 2025.
Nine-month net loss was $70.6 million ($0.38 per share) versus $50.8 million ($0.34 per share) a year earlier.
Cash and marketable securities were $163 million at September 30, 2026, down from $209 million at December 31, 2025, with $48 million used in operating activities.
Bicara Therapeutics reported a third-quarter 2026 net loss of $71.2 million, nearly double the $36.3 million loss a year earlier, as research and development and general and administrative costs rose for its pivotal trial and commercial preparation. The company said its $442.3 million in cash and marketable securities should fund operations into the first half of 2029, and it reiterated that topline interim results from the FORTIFI-HN01 pivotal trial are expected in mid-2027.
Net loss was $71.2 million for the quarter ended September 30, 2026, versus $36.3 million a year earlier.
Research and development expenses rose to $56.5 million from $33.0 million; general and administrative expenses rose to $19.2 million from $7.7 million.
Cash, cash equivalents and marketable securities were $442.3 million at September 30, 2026, which the company expects to fund operations into the first half of 2029.
Topline interim results from the FORTIFI-HN01 pivotal trial are expected in mid-2027.
Popular, Inc. filed an 8-K updating its third-quarter 2026 results after a commercial borrower in the quick service restaurant industry substantially ceased operations and filed for Chapter 11 bankruptcy following the earnings release. The company recognized an additional $38 million provision for credit losses, lowering quarterly net income to $242.4 million from $266.3 million and diluted EPS to $3.83 from $4.21, and it raised its 2026 net charge-off guidance to 90 bps to 95 bps from 80 bps to 90 bps.
Q3 2026 net income of $242.4 million, down $23.9 million from the $266.3 million in the original earnings release.
Diluted EPS of $3.83 versus $4.21 as originally issued; up from $3.14 in the same quarter of 2025.
The company expects an additional fourth-quarter 2026 charge-off on the same relationship.
2026 net charge-off guidance raised to 90 bps to 95 bps from 80 bps to 90 bps; Common Equity Tier 1 ratio of 16.01%, down 5 bps.
Tango Therapeutics reported a third quarter 2026 net loss of $68.4 million, or $0.39 per share, compared with net income of $15.9 million, or $0.13 per diluted share, in the same quarter of 2025. Collaboration revenue fell to $0 from $53.8 million after the Gilead collaboration concluded research activities in August 2025, while research and development and general and administrative spending both rose.
Collaboration revenue was $0 in Q3 2026, versus $53.8 million in Q3 2025.
R&D expenses rose to $48.9 million from $30.8 million; G&A expenses rose to $29.2 million from $8.9 million.
Cash, cash equivalents and marketable securities totaled $977.5 million as of September 30, 2026.
Tango intends to initiate a Phase 3 study of vopimetostat plus daraxonrasib in front-line pancreatic cancer in the first half of 2027.
Ocular Therapeutix reported third quarter 2026 results with total net revenue of $12.9 million, down from $14.5 million a year earlier, and a net loss of $94.8 million, or $(0.42) per share, versus a net loss of $69.4 million, or $(0.38) per share, in the prior-year quarter. Research and development expenses rose to $74.8 million from $52.4 million, and the company said it had $530.6 million in cash as of September 30, 2026, with runway expected into 2028.
Net revenue was $12.9 million for Q3 2026, compared with $14.5 million for Q3 2025.
Net loss was $(94.8) million, or $(0.42) per share, versus $(69.4) million, or $(0.38) per share, a year earlier.
R&D expenses were $74.8 million versus $52.4 million, reflecting faster HELIOS-3 and SOL-X enrollment and higher headcount.
Cash and cash equivalents were $530.6 million as of September 30, 2026; the company expects this to support operations into 2028.
Aura Biosciences reported third quarter 2026 results, with a net loss of $32.1 million, up from $26.1 million a year earlier. The company said a $4.5 million restructuring charge, tied to its reorganization around its ocular oncology portfolio, contributed to higher general and administrative expenses, and it reiterated that its cash is expected to last into the first half of 2029.
Net loss of $32.1 million for the quarter ended September 30, 2026, versus $26.1 million a year earlier; loss per share was $0.29, versus $0.40.
General and administrative expenses rose to $10.3 million from $5.7 million, driven mainly by restructuring charges of approximately $4.5 million.
Research and development expenses rose to $24.7 million from $22.2 million, tied to the Phase 3 CoMpass trial.
Cash, cash equivalents and marketable securities totaled $297.2 million as of September 30, 2026.
Virtus Investment Partners reported third-quarter 2026 results for the period ended September 30, 2026, with GAAP revenue of $197.6 million, down 9% from a year earlier, and diluted EPS of $3.26 versus $4.65. Assets under management fell 16% year over year to $141.4 billion, with net outflows of $6.1 billion, which weighs on future fee revenue for shareholders.
GAAP diluted EPS was $3.26 versus $4.65 a year earlier and $6.68 in the prior quarter; adjusted diluted EPS was $5.86 versus $7.35 a year earlier.
Revenue was $197.6 million, down 9% from $216.4 million a year earlier and down 2% from $201.4 million in the prior quarter.
Ending assets under management were $141.4 billion, down from $169.3 billion a year earlier, with net outflows of $6.1 billion.
The company repurchased 64,666 shares for $10.0 million and raised its quarterly dividend 2% to $2.45 per share.
Ispire Technology reported results for the quarter ended September 30, 2026. Revenue fell 9.3% from a year earlier, mainly on lower European sales, and the net loss widened to $6.4 million from $3.3 million, largely due to $4.8 million of credit loss expense. Compared with the prior quarter, revenue rose 3.2% and the net loss narrowed, and adjusted EBITDA turned positive at $136,000.
Revenue was $27.5 million, down from $30.4 million a year earlier, and up 3.2% from $26.7 million in the prior quarter.
Net loss was $6.4 million, or $(0.11) per share, versus $3.3 million, or $(0.06) per share, a year earlier.
Credit loss expense rose to $4.8 million from $1.8 million; adjusted EBITDA was $136,000 versus $0.6 million a year earlier.
Gross margin was 16.2%, compared with 17.0% a year earlier and 6.3% in the prior quarter.
Turn Therapeutics reported a third-quarter 2026 net loss of $6.2 million, or $(0.21) per share, up from $1.9 million, or $(0.07) per share, a year earlier. The company said its $10.4 million in cash as of September 30, 2026 is expected to fund operations into the third quarter of 2027, which matters to shareholders given the higher loss and the need for further capital.
Q3 2026 net loss was $6.2 million, or $(0.21) per basic and diluted share, versus $1.9 million, or $(0.07), in Q3 2025
Net loss from change in fair value of derivative liability instrument was $3.3 million in the quarter, compared with none in the prior-year period
Cash and cash equivalents were $10.4 million at September 30, 2026, with operations expected to be funded into the third quarter of 2027
loanDepot reported a third-quarter 2026 net loss of $29 million, up from $7 million in the prior quarter, on total revenue of $307 million, down 9% from $337 million. Origination volume fell 12% sequentially to $7.05 billion, though it rose 8% from a year earlier, and the company said higher interest rates and a difficult housing market weighed on results.
Net loss of $29 million versus $7 million in Q2 2026; diluted loss per share of $0.08 versus $0.02
Adjusted EBITDA of $17 million, down from $20 million in Q2 2026
Sold $10 billion of Agency mortgage servicing rights; agreed to sell another $9 billion of Government MSRs, which closed in October
Repurchased $87 million of senior notes at an average 88% of par; company is pursuing financing alternatives to refinance or extend debt
bioAffinity Technologies reported third-quarter 2026 revenue of approximately $1.1 million, down from approximately $1.4 million a year earlier, which it attributed to lower reimbursement per CyPath Lung test and a slight decline in cases at its Precision Pathology Laboratory Services subsidiary. The net loss widened to approximately $5.3 million from $5.1 million, as the operating loss grew to approximately $3.5 million from $2.3 million, and cash fell to approximately $2.6 million at September 30, 2026, which matters to shareholders given the company's continuing losses.
Q3 2026 revenue was approximately $1.1 million versus approximately $1.4 million in Q3 2025; nine-month CyPath Lung testing revenue rose 79% to approximately $1.1 million.
Q3 net loss was approximately $5.3 million versus $5.1 million; loss from operations was approximately $3.5 million versus $2.3 million.
Cash and cash equivalents were approximately $2.6 million at September 30, 2026, down from $6.4 million at December 31, 2025; a financing after quarter-end generated approximately $4.0 million in gross proceeds.
Sidus Space's audit committee concluded that its audited 2024 and 2025 annual reports and its 2026 quarterly reports for March 31 and June 30 should no longer be relied upon. The company expects the restatements to increase net loss for 2024 and for the first half of 2026, decrease net loss for 2025, and reduce stockholders' equity in every affected period, and it expects to report material weaknesses in internal controls.
Restatement covers the 2024 and 2025 annual reports and the Q1 and Q2 2026 quarterly reports; the 2024 and 2025 10-Ks were filed March 31, 2025 and April 1, 2026.
Net loss expected to increase by about $12.5 million for 2024 and about $4.1 million for the six months ended June 30, 2026; net loss expected to decrease by about $5.5 million for 2025.
Total stockholders' equity expected to decrease by about $15.0 million as of June 30, 2026, compared with amounts originally reported.
Main cause is warrant classification: 3,409,946 warrants issued December 17, 2024 should have been recorded as liabilities; the company also cited a $4.0 million impairment on its LS-2 satellite.
Quoin Pharmaceuticals reported a net loss of $4.9 million for the quarter ended September 30, 2026, up from $3.9 million a year earlier, and a nine-month net loss of $15.2 million versus $11.5 million. The company said it had about $33.2 million in cash, cash equivalents and marketable securities at quarter end, and it highlighted positive interim Netherton Syndrome data and new regulatory designations. Shareholders see a wider loss alongside clinical and regulatory progress.
Q3 2026 net loss was approximately $4.9 million, compared with approximately $3.9 million in Q3 2025.
Nine-month 2026 net loss was approximately $15.2 million, compared with approximately $11.5 million for the same period in 2025.
Cash, cash equivalents and marketable securities were approximately $33.2 million as of September 30, 2026.
Up to $50.0 million private placement was announced August 28, 2026, with approximately $30.8 million in initial upfront funding.
FB Bancorp reported third-quarter 2026 net income of $466 thousand, down from $1.1 million a year earlier, as non-interest expenses rose and net interest margin fell to 4.30% from 4.65%. Nine-month net income was $515 thousand versus $2.7 million, including a $1.1 million loss from discontinued mortgage banking operations. Shareholders face lower earnings and a commercial loan of approximately $19.8 million now classified as substandard.
Q3 2026 net income was $466 thousand versus $1.1 million in Q3 2025; continuing operations EPS was $0.03 versus $0.06.
Nine-month 2026 net income was $515 thousand, including a $1.1 million loss from discontinued operations, versus $2.7 million a year earlier.
Non-interest expenses rose $390 thousand, or 3.33%, in Q3 2026 year over year, with $686 thousand of stock-based compensation.
A commercial loan with a principal balance of approximately $19.8 million was classified substandard after two co-borrower entities filed for Chapter 11 in June 2026; no specific allowance was recorded.
Entera Bio reported a third-quarter 2026 net loss of $15.6 million, or $0.11 per share, up from $3.2 million, or $0.07 per share, a year earlier. The company reported no revenue in either period, and the filing attributes the increase mainly to a $7.5 million non-cash fair value remeasurement of pre-funded warrants. Shareholders also got an update that the first clinical site for the EB613 Phase 3 osteoporosis study is expected to be activated in late 2026, with cash of $265.9 million as of September 30, 2026.
Net loss was $15.6 million for the three months ended September 30, 2026, compared with $3.2 million a year earlier.
The loss increase was primarily driven by a $7.5 million non-cash fair value remeasurement of pre-funded warrants.
Research and development expenses rose to $4.9 million from $1.6 million, mainly for EB613 Phase 3 start-up and the OPKO collaboration.
Cash and cash equivalents were $265.9 million as of September 30, 2026, following a July 2026 private placement with gross proceeds of approximately $275.0 million.
Gogo reported third quarter 2026 revenue of $213.2 million, down 5% from a year earlier, and a net loss of $3.2 million, compared with a $1.9 million loss in the same period of 2025. The company reiterated its 2026 guidance and said it amended and extended its roughly $600 million Term Loan B to October 2030, with $75 million in principal repayments committed through 2027.
Total revenue of $213.2 million, down 5% year over year; Military/Government service revenue rose 36% to $37.2 million
Net loss of $3.2 million (diluted loss of $0.02 per share) versus a $1.9 million loss in Q3 2025; Adjusted EBITDA of $41.0 million, down 27%
2026 guidance reiterated: total revenue of $870 million to $895 million and Adjusted EBITDA of $175 million to $185 million
Term Loan B extended to October 2030, with $30 million to be repaid by December 31, 2026 and $20 million more by December 31, 2027
CG Oncology reported a third-quarter 2026 net loss of $56.9 million, or $(0.64) per share, up from $43.8 million, or $(0.57) per share, a year earlier. Total revenue was $1.6 million, down from $1.7 million, while research and development expenses rose to $39.2 million from $27.9 million. Cash, cash equivalents and marketable securities were $984.5 million at September 30, 2026, which the company expects will fund operations through 2029.
Net loss of $56.9 million, or $(0.64) per share, for the quarter ended September 30, 2026, versus $43.8 million, or $(0.57) per share, a year earlier
Total revenue of $1.6 million, compared with $1.7 million in the prior-year quarter
Research and development expenses of $39.2 million, up from $27.9 million, mainly due to higher clinical trial costs and headcount-related compensation
PIVOT-006 Phase 3 topline data expected November 2026; BLA completion for BCG-unresponsive NMIBC expected in Q4 2026
Tredegar reported a third-quarter 2026 net loss from continuing operations of $2.8 million, or $0.08 per diluted share, compared with net income of $7.1 million, or $0.20 per share, a year earlier. Management said results were not where it wants them to be, citing lower building and construction demand at Bonnell Aluminum and weaker Surface Protection demand at High Performance Films. The results are a sharp drop in profitability for shareholders, and the filing gives no updated full-year guidance.
Q3 2026 net loss from continuing operations of $2.8 million, or $0.08 per diluted share, vs. net income of $7.1 million, or $0.20 per share, in Q3 2025
Q3 2026 Consolidated EBITDA from ongoing operations of $4.1 million, vs. $18.1 million in Q3 2025
Aluminum Extrusions Q3 2026 EBITDA from ongoing operations of $2.5 million, vs. $16.8 million in Q3 2025; sales volume fell 11.6%
Net debt rose to $32.7 million at September 30, 2026, from $28.4 million at December 31, 2025
Protara Therapeutics reported third quarter 2026 results, with a net loss of $21.7 million, or $0.35 per share, compared with a net loss of $13.3 million, or $0.31 per share, a year earlier. Research and development expenses rose to $16.8 million from $9.6 million, and the company said cash, cash equivalents and marketable debt securities of $143.1 million should fund operations into 2028.
Q3 2026 net loss of $21.7 million ($0.35 per share) vs. $13.3 million ($0.31 per share) in Q3 2025
R&D expenses rose to $16.8 million from $9.6 million, mainly from higher clinical trial costs of $4.4 million
Cash and marketable debt securities totaled $143.1 million as of September 30, 2026
On November 4, 2026, the company agreed to buy TARA-002 manufacturing-related assets from Novex Innovations for $8.75 million
TechTarget reported third-quarter 2026 revenue of $119.2 million, down 2.5% from a year earlier, and said it now expects full-year 2026 revenue to be modestly lower than 2025. Its net loss narrowed sharply from the prior year, which included large goodwill impairment charges, but Adjusted EBITDA fell and the company gave a full-year 2026 Adjusted EBITDA range of $80 million to $85 million.
Q3 2026 revenue was $119.2 million, versus $122.3 million in Q3 2025; nine-month revenue was $341.4 million, versus $346.1 million
Q3 2026 net loss was $18.2 million, versus $76.8 million in Q3 2025; Q3 Adjusted EBITDA was $18.6 million, versus $22.6 million
Full-year 2026 Adjusted EBITDA outlook is $80 million to $85 million, with full-year revenue expected to be modestly lower than 2025
Cash was $35.3 million at September 30, 2026, with $120.1 million drawn on a $250 million revolving credit facility
Telephone and Data Systems reported third quarter 2026 total operating revenues of $306.7 million, down from $308.5 million a year earlier, and net income attributable to TDS common shareholders of $29.6 million from continuing operations, compared with $40.2 million. The company lowered TDS Telecom's 2026 revenue, Adjusted OIBDA and Adjusted EBITDA guidance, raised its capital expenditure estimate, and its board approved an incremental $250 million share repurchase authorization.
Q3 2026 diluted EPS from continuing operations was $0.26, versus $0.33 in Q3 2025; total operating revenues were $306.7 million versus $308.5 million.
TDS Telecom 2026 revenue guidance was cut to $990 million to $1,010 million from $1,000 million to $1,025 million; Adjusted OIBDA guidance was cut to $280 million to $300 million from $300 million to $320 million.
TDS Telecom capital expenditure guidance was raised to approximately $750 million from $625 million to $675 million.
The board approved an incremental $250 million share repurchase authorization; TDS repurchased about 6 million shares in the quarter at an average price of $36.65.
Ziff Davis reported unaudited third quarter 2026 results, with revenue down 5.6% from a year earlier and a swing to an operating loss of $33.6 million, including a $29.6 million goodwill impairment. Adjusted diluted EPS was $1.39 versus $1.40 a year earlier, and the company repurchased $92.0 million of its shares during the quarter. The company will discuss the results on a call on November 6, 2026.
Revenue was $289.3 million versus $306.5 million in Q3 2025; adjusted EBITDA was $82.2 million versus $97.8 million.
Net loss from continuing operations was $28.7 million, or $0.85 per diluted share, compared with a loss of $16.0 million, or $0.39 per share, in Q3 2025.
Adjusted diluted EPS was $1.39 compared with $1.40 a year earlier.
Share repurchases totaled $92.0 million in Q3 2026 and approximately $265 million for the first three quarters of 2026.
Revelation Biosciences reported results for the three and nine months ended September 30, 2026, with no revenue line in the filing. The net loss grew from a year earlier, and cash fell from $10.7 million at December 31, 2025 to $9.1 million, which the company says will fund operations into the second quarter of 2027.
Net loss for the three months ended September 30, 2026 was $3.3 million, compared with $1.9 million a year earlier.
Net loss for the nine months ended September 30, 2026 was $9.6 million, compared with $6.4 million a year earlier.
Cash and cash equivalents were $9.1 million at September 30, 2026, versus $10.7 million at December 31, 2025; the company expects this to fund operations into the second quarter of 2027.
Net cash used for operating activities was $2.6 million for the third quarter of 2026, compared with $1.6 million in the same period of 2025.
Brighthouse Financial reported third quarter 2026 net income available to shareholders of $302 million, or $5.21 per diluted share, down from $453 million, or $7.89 per share, a year earlier. Adjusted earnings fell to $527 million, or $9.12 per share, from $970 million, or $16.87 per share, though the company said its annual actuarial review added $314 million of net favorable notable items. The company also said regulatory approvals for the pending $70.00 per share Aquarian Capital acquisition are not expected before the December 6, 2026 Outside Date, and the parties are discussing an extension.
Net income available to shareholders was $302 million, or $5.21 per diluted share, versus $453 million, or $7.89 per share, in the third quarter of 2025.
Adjusted earnings, less notable items, were $213 million, or $3.68 per diluted share, versus $261 million, or $4.54 per share, a year earlier.
Annuity sales were $2.4 billion, including $2.1 billion of Shield Level Annuities, with annuity sales down 12% quarter-over-quarter.
The merger agreement's Outside Date is December 6, 2026; the company and Aquarian Capital are discussing an extension, with no assurance of agreement.
Ready Capital reported a third-quarter 2026 GAAP net loss of $62.2 million, or $(0.40) per share, compared with a net loss of $16.7 million, or $(0.13) per share, a year earlier. Distributable loss was $(0.53) per share, and the company declared $0.01 per common share in dividends, down from $0.125 a year earlier, which matters to shareholders because it reflects weaker earnings and a much smaller dividend.
Q3 2026 GAAP loss per common share of $(0.40), versus $(0.13) in Q3 2025; nine-month loss per share of $(2.27)
Distributable loss per common share of $(0.53); before realized losses, $(0.21)
Dividends declared per common share of $0.01 in Q3 2026, versus $0.125 in Q3 2025
Book value of $6.44 per common share as of September 30, 2026; cash of $157 million and total leverage of 2.8x
PLAYSTUDIOS reported third-quarter 2026 revenue of $48.9 million, down from $57.6 million a year earlier, and a net loss of $11.0 million, up from $9.1 million. The company discontinued two products, Tetris Block Party and The Win Zone, and recorded $6.7 million in non-cash impairment charges plus a $9.2 million goodwill impairment. It is not providing formal financial guidance, which leaves shareholders without a forward outlook.
Q3 2026 revenue was $48.9 million versus $57.6 million in Q3 2025; direct-to-consumer revenue rose 108% to $16.0 million.
Net loss was $11.0 million versus $9.1 million; Consolidated AEBITDA rose to $10.0 million from $7.2 million.
Goodwill impairment of $9.2 million and a $6.7 million non-cash impairment charge tied to the discontinued products.
No formal financial guidance was provided; restructuring annualized savings range was raised to $37.0 million to $39.0 million, with $44.6 million left on the share repurchase authorization.
BRT Apartments reported a wider net loss for the third quarter ended September 30, 2026, with a loss of $0.23 per diluted share versus $0.14 a year earlier. Funds from operations (FFO) and adjusted FFO (AFFO) per diluted share also declined, to $0.26 and $0.31 from $0.28 and $0.36, and combined portfolio net operating income slipped to $15.1 million from $15.3 million. The company declared a $0.25 per share dividend for the quarter.
Net loss attributable to common stockholders was $3.955 million, or $0.23 per diluted share, for Q3 2026, versus $2.707 million, or $0.14, in Q3 2025.
FFO per diluted share was $0.26, down from $0.28; AFFO per diluted share was $0.31, down from $0.36.
Combined portfolio NOI was $15.1 million for Q3 2026 compared with $15.3 million a year earlier.
A $0.25 per share dividend was declared for the third quarter of 2026.
Nkarta reported third-quarter 2026 results, with a net loss of $33.3 million, or $0.45 per share, compared with a net loss of $21.7 million, or $0.29 per share, a year earlier. The company said its $216.0 million in cash, cash equivalents, restricted cash and investments as of September 30, 2026, is expected to fund operations into 2029. Higher research and development spending drove the larger loss, and shareholders face continued losses while the company's lead candidate is still in clinical trials.
Q3 2026 net loss of $33.3 million ($0.45 per share), up from $21.7 million ($0.29 per share) in Q3 2025
R&D expenses rose to $29.5 million from $20.2 million; G&A expenses fell to $6.3 million from $7.1 million
Cash and investments were $216.0 million on September 30, 2026, down from $295.1 million on December 31, 2025
Initial NKX019 clinical data to be presented at ACR Convergence 2026, with an oral presentation on November 8
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.